This entry passed through the Full-Text RSS service - if this is your content and you're reading it on someone else's site, please read the FAQ at http://ift.tt/jcXqJW.
Thursday 14 May 2015 - 12:13 Makkah mean time-25-7-1436
Lung cancer (Google images)
Havana (IINA) - More than 100 Cuban and foreign researchers gathered here to continue evaluating the progress and new actions of CIMAvax-EGF, the first therapeutic registered vaccine for lung cancer, according to media reports.
The conference, which opened Wednesday at Havana's Conference Center, provided an opportunity to assess new strategies in the control and dispensation of the medicine.
Dr Agustin Lage, director of the Center of Molecular Immunology, talked at the opening ceremony about the use of therapeutic vaccines as part of cancer treatment.
He stated that globally, of all patients with malignant tumors, about three percent are receiving some form of immunotherapy, and the prediction is that in the coming decade this kind of therapy will reach 60 percent.
"The questions today is not whether immunotherapy effective or not, but how long it has to be administered and in which patients,” said Dr Lage, adding that Cimavax-EGF is making its way worldwide.
Several clinical trials are being conducted in European and Latin American countries, and the interest for the product is growing, as that showed by U.S. scientists who recently visited Cuba.
AB/IINA
|
No comments:
Post a Comment